Adapting high-throughput screening methods and assays for biocontainment laboratories

Lynn Rasmussen, Bersabeh Tigabu, E. Lucile White, Robert Bostwick, Nichole Tower, Alexander Bukreyev, Barry Rockx, James LeDuc, James W. Noah

Research output: Contribution to journalArticle

4 Citations (Scopus)

Abstract

High-throughput screening (HTS) has been integrated into the drug discovery process, and multiple assay formats have been widely used in many different disease areas but with limited focus on infectious agents. In recent years, there has been an increase in the number of HTS campaigns using infectious wild-type pathogens rather than surrogates or biochemical pathogen-derived targets. Concurrently, enhanced emerging pathogen surveillance and increased human mobility have resulted in an increase in the emergence and dissemination of infectious human pathogens with serious public health, economic, and social implications at global levels. Adapting the HTS drug discovery process to biocontainment laboratories to develop new drugs for these previously uncharacterized and highly pathogenic agents is now feasible, but HTS at higher biosafety levels (BSL) presents a number of unique challenges. HTS has been conducted with multiple bacterial and viral pathogens at both BSL-2 and BSL-3, and pilot screens have recently been extended to BSL-4 environments for both Nipah and Ebola viruses. These recent successful efforts demonstrate that HTS can be safely conducted at the highest levels of biological containment. This review outlines the specific issues that must be considered in the execution of an HTS drug discovery program for high-containment pathogens. We present an overview of the requirements for HTS in high-level biocontainment laboratories.

Original languageEnglish (US)
Pages (from-to)44-54
Number of pages11
JournalAssay and Drug Development Technologies
Volume13
Issue number1
DOIs
StatePublished - Feb 1 2015

Fingerprint

High-Throughput Screening Assays
Drug Discovery
Nipah Virus
Ebolavirus
Containment of Biohazards
Public Health
Economics
Pharmaceutical Preparations

ASJC Scopus subject areas

  • Drug Discovery
  • Molecular Medicine

Cite this

Adapting high-throughput screening methods and assays for biocontainment laboratories. / Rasmussen, Lynn; Tigabu, Bersabeh; White, E. Lucile; Bostwick, Robert; Tower, Nichole; Bukreyev, Alexander; Rockx, Barry; LeDuc, James; Noah, James W.

In: Assay and Drug Development Technologies, Vol. 13, No. 1, 01.02.2015, p. 44-54.

Research output: Contribution to journalArticle

Rasmussen, Lynn ; Tigabu, Bersabeh ; White, E. Lucile ; Bostwick, Robert ; Tower, Nichole ; Bukreyev, Alexander ; Rockx, Barry ; LeDuc, James ; Noah, James W. / Adapting high-throughput screening methods and assays for biocontainment laboratories. In: Assay and Drug Development Technologies. 2015 ; Vol. 13, No. 1. pp. 44-54.
@article{bc0ad93606724b8f9a90d50ae83a4797,
title = "Adapting high-throughput screening methods and assays for biocontainment laboratories",
abstract = "High-throughput screening (HTS) has been integrated into the drug discovery process, and multiple assay formats have been widely used in many different disease areas but with limited focus on infectious agents. In recent years, there has been an increase in the number of HTS campaigns using infectious wild-type pathogens rather than surrogates or biochemical pathogen-derived targets. Concurrently, enhanced emerging pathogen surveillance and increased human mobility have resulted in an increase in the emergence and dissemination of infectious human pathogens with serious public health, economic, and social implications at global levels. Adapting the HTS drug discovery process to biocontainment laboratories to develop new drugs for these previously uncharacterized and highly pathogenic agents is now feasible, but HTS at higher biosafety levels (BSL) presents a number of unique challenges. HTS has been conducted with multiple bacterial and viral pathogens at both BSL-2 and BSL-3, and pilot screens have recently been extended to BSL-4 environments for both Nipah and Ebola viruses. These recent successful efforts demonstrate that HTS can be safely conducted at the highest levels of biological containment. This review outlines the specific issues that must be considered in the execution of an HTS drug discovery program for high-containment pathogens. We present an overview of the requirements for HTS in high-level biocontainment laboratories.",
author = "Lynn Rasmussen and Bersabeh Tigabu and White, {E. Lucile} and Robert Bostwick and Nichole Tower and Alexander Bukreyev and Barry Rockx and James LeDuc and Noah, {James W.}",
year = "2015",
month = "2",
day = "1",
doi = "10.1089/adt.2014.617",
language = "English (US)",
volume = "13",
pages = "44--54",
journal = "Assay and Drug Development Technologies",
issn = "1540-658X",
publisher = "Mary Ann Liebert Inc.",
number = "1",

}

TY - JOUR

T1 - Adapting high-throughput screening methods and assays for biocontainment laboratories

AU - Rasmussen, Lynn

AU - Tigabu, Bersabeh

AU - White, E. Lucile

AU - Bostwick, Robert

AU - Tower, Nichole

AU - Bukreyev, Alexander

AU - Rockx, Barry

AU - LeDuc, James

AU - Noah, James W.

PY - 2015/2/1

Y1 - 2015/2/1

N2 - High-throughput screening (HTS) has been integrated into the drug discovery process, and multiple assay formats have been widely used in many different disease areas but with limited focus on infectious agents. In recent years, there has been an increase in the number of HTS campaigns using infectious wild-type pathogens rather than surrogates or biochemical pathogen-derived targets. Concurrently, enhanced emerging pathogen surveillance and increased human mobility have resulted in an increase in the emergence and dissemination of infectious human pathogens with serious public health, economic, and social implications at global levels. Adapting the HTS drug discovery process to biocontainment laboratories to develop new drugs for these previously uncharacterized and highly pathogenic agents is now feasible, but HTS at higher biosafety levels (BSL) presents a number of unique challenges. HTS has been conducted with multiple bacterial and viral pathogens at both BSL-2 and BSL-3, and pilot screens have recently been extended to BSL-4 environments for both Nipah and Ebola viruses. These recent successful efforts demonstrate that HTS can be safely conducted at the highest levels of biological containment. This review outlines the specific issues that must be considered in the execution of an HTS drug discovery program for high-containment pathogens. We present an overview of the requirements for HTS in high-level biocontainment laboratories.

AB - High-throughput screening (HTS) has been integrated into the drug discovery process, and multiple assay formats have been widely used in many different disease areas but with limited focus on infectious agents. In recent years, there has been an increase in the number of HTS campaigns using infectious wild-type pathogens rather than surrogates or biochemical pathogen-derived targets. Concurrently, enhanced emerging pathogen surveillance and increased human mobility have resulted in an increase in the emergence and dissemination of infectious human pathogens with serious public health, economic, and social implications at global levels. Adapting the HTS drug discovery process to biocontainment laboratories to develop new drugs for these previously uncharacterized and highly pathogenic agents is now feasible, but HTS at higher biosafety levels (BSL) presents a number of unique challenges. HTS has been conducted with multiple bacterial and viral pathogens at both BSL-2 and BSL-3, and pilot screens have recently been extended to BSL-4 environments for both Nipah and Ebola viruses. These recent successful efforts demonstrate that HTS can be safely conducted at the highest levels of biological containment. This review outlines the specific issues that must be considered in the execution of an HTS drug discovery program for high-containment pathogens. We present an overview of the requirements for HTS in high-level biocontainment laboratories.

UR - http://www.scopus.com/inward/record.url?scp=84923343289&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84923343289&partnerID=8YFLogxK

U2 - 10.1089/adt.2014.617

DO - 10.1089/adt.2014.617

M3 - Article

C2 - 25710545

AN - SCOPUS:84923343289

VL - 13

SP - 44

EP - 54

JO - Assay and Drug Development Technologies

JF - Assay and Drug Development Technologies

SN - 1540-658X

IS - 1

ER -